ArticleNeuro-oncology2012
Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.
Article in Neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Centratherin Exhibits Antitumor Activity Against Glioblastoma Cells.Neurochemical research · 2026Article
- Review
- A foretaste for pediatric glioblastoma therapy: targeting the NF-kB pathway with DHMEQ.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Article
- The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?Cellular and molecular life sciences : CMLS · 2021Review
- Natural Small Molecules Targeting NF-κB Signaling in Glioblastoma.Frontiers in pharmacology · 2021Review
- Anticancer Activity of Novel NF-kappa B Inhibitor DHMEQ by Intraperitoneal Administration.Oncology research · 2020Review
- Identification of a Selective RelA Inhibitor Based on DSE-FRET Screening Methods.International journal of molecular sciences · 2020Article
- NF-кB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Article
- Aberrant methylation and silencing of the SPINT2 gene in high-grade gliomas.Cancer science · 2018Article
- Natural products: a hope for glioblastoma patients.Oncotarget · 2018Review
- Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.International journal of molecular sciences · 2018Review
- CISD2 promotes the proliferation of glioma cells via suppressing beclin‑1‑mediated autophagy and is targeted by microRNA‑449a.Molecular medicine reports · 2017Article
- Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications.BioMed research international · 2017Review
- Inhibition of nuclear factor-κB signaling suppresses Spint1-deletion-induced tumor susceptibility in the ApcMin/+ model.Oncotarget · 2016Article
- Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats.International journal of molecular medicine · 2016Article
- The NF-κB Pathway and Cancer Stem Cells.Cells · 2016Review
- Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy.Neuro-oncology · 2016Review
- NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.Expert review of neurotherapeutics · 2014Review
- Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy.PloS one · 2014Article
- Polish natural bee honeys are anti-proliferative and anti-metastatic agents in human glioblastoma multiforme U87MG cell line.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is the most malignant type of brain tumor. Despite recent advances in therapeutic modalities, the prognosis of glioblastoma remains very poor. Recent studies have indicated that RelA/nuclear factor (NF)-κB is consistently activated in human glioblastoma. In this study, we searched for a new treatment modality for glioblastoma, by examining the effects of dehydroxymethylepoxyquinomicin (DHMEQ), a unique small molecule inhibitor of NF-κB. Addition of DHMEQ to cultured human glioblastoma cells inhibited the nuclear translocation of RelA. It also reduced the growth rate of human glioblastoma cells significantly in 6 cell lines and modestly in 3 among 10 cell lines examined. Then, we performed further analyses using 3 sensitive cell lines (U87, U251, and YKG-1). The growth retardation was accompanied by G2/M arrest in vitro. Increased apoptosis was observed in U87 and YKG-1, but not U251 cells after DHMEQ treatment. Then, we tested the efficacy of DHMEQ in chemoprevention through the use of a nude mouse model. Subcutaneous tumors formed by U87 or U251 cells were reduced by ∼40% in size by intraperitoneal administration of DHMEQ started immediately after implantation of the cells. DHMEQ treatment achieved statistically significant improvements in survival curves of mice intracranially implanted with U87 or U251 cells. Histological analysis revealed increased areas of necrosis, increased numbers of collapsed microvessels, decreased nuclear immunoreactivity of RelA, and decreased immunoreactivity of urokinase-type plasminogen activator in the DHMEQ-treated U87 tumor tissues. These results suggest that the targeting of NF-κB by DHMEQ may serve as a promising treatment modality in glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.